Kyowa Kirin Co Ltd represents a set of core values and corporate philosophy. The company prioritizes the health and well-being of patients, aiming to contribute to the advancement of medical science and enhance the quality of life. Kyowa Kirin Co Ltd focuses on innovation, putting patient needs at the forefront of its research and development activities. The company believes in collaboration and partnerships to drive progress in delivering novel therapies and addressing unmet medical needs. With a commitment to integrity and ethical business practices, Kyowa Kirin Co Ltd strives to make a positive impact and improve the lives of patients worldwide.

Kyowa Kirin Co Ltd is primarily present in Japan, where it is headquartered. Additionally, the company has a significant presence in other countries and regions worldwide. These include the United States, where it operates through a subsidiary, as well as various regions in Europe, including the United Kingdom, Germany, France, and Switzerland. With a global reach and a strong presence in multiple markets, Kyowa Kirin Co Ltd is able to leverage its expertise and product offerings across different regions to optimize its business operations and serve a diverse customer base effectively.

Kyowa Kirin Co Ltd, a leading pharmaceutical company, has achieved noteworthy milestones over the years. Notably, the company successfully developed and launched several groundbreaking medicines, such as Poteligeo, a treatment for skin conditions like cutaneous T-cell lymphoma. Additionally, Kyowa Kirin Co Ltd secured regulatory approvals for novel therapies like CRYSVITA, a treatment for rare bone diseases. Furthermore, the company built strategic alliances and partnerships to expand its global footprint and enhance research capabilities. In recent years, Kyowa Kirin Co Ltd has shown a strong commitment to innovation and patient care, continuously striving to improve the lives of individuals worldwide through its breakthrough advancements.

Kyowa Kirin Co Ltd, formerly known as Kyowa Hakko Kirin Co Ltd, is a leading Japanese pharmaceutical company. Founded in 1949, it has a rich history and background in the healthcare sector. Kyowa Kirin specializes in the research, development, manufacturing, and marketing of innovative and life-saving pharmaceuticals. Over the years, the company has been dedicated to delivering high-quality medicines for a wide range of diseases, including cancer, renal diseases, and immune disorders. With a strong emphasis on scientific research and technological advancements, Kyowa Kirin has established itself as a trusted and reliable name in the global pharmaceutical industry.

The main competitors of Kyowa Kirin Co Ltd in the market include other pharmaceutical and biotechnology companies such as Takeda Pharmaceutical Company Limited, Eisai Co Ltd, and Astellas Pharma Inc. These companies also operate in the healthcare sector, developing and selling various drugs and therapies. Kyowa Kirin Co Ltd competes with these companies in terms of research and development, product pipelines, market share, and global presence.

Kyowa Kirin Co Ltd is primarily active in the pharmaceutical and biotechnology industries.

The business model of Kyowa Kirin Co Ltd is focused on the development, manufacturing, and commercialization of specialty pharmaceuticals. The company primarily operates in the fields of nephrology, oncology, and immunology. Kyowa Kirin Co Ltd strives to bring innovative and high-quality therapeutic solutions to patients worldwide. With a strong commitment to research and development, the company invests in advancements in biotechnology and strives to address unmet medical needs. Kyowa Kirin Co Ltd also collaborates with global partners to expand its product portfolio and reach a wider patient population, all while maintaining a strong focus on patient-centricity and improving healthcare outcomes.

Raportul Kyowa Kirin Co preț/beneficiu este 24,67.

Raportul Kyowa Kirin Co preț/vânzări este 3,45.

Scorul de calitate AlleAktien pentru Kyowa Kirin Co este 7/10.

Cifra de afaceri a așteptată Kyowa Kirin Co este de 482,83 mld. JPY.

Profitul așteptată Kyowa Kirin Co este 67,57 mld. JPY.

Kyowa Kirin Co Ltd is a global pharmaceutical company based in Japan that focuses on the development, manufacturing, and marketing of medications for patients with rare diseases. The company's business operations are divided into four segments: 1. Pharmaceutical Business: Kyowa Kirin focuses on researching and developing innovative medications for patients with rare diseases or unmet medical needs. The portfolio includes treatments for diseases such as kidney diseases, cancer, blood disorders, immunological diseases, neurological diseases, and heart diseases. 2. Bio-Chemicals Business: Kyowa Kirin produces biochemical products for biotech companies and research institutions worldwide. The company is capable of manufacturing a wide range of biochemicals, enzymes, reagents, and active ingredients at the highest level. 3. Vaccines Business: Kyowa Kirin focuses on developing vaccines against life-threatening diseases in this segment. Kyowa Kirin's experts have decades of experience in vaccine development, significantly supporting the containment of infectious diseases. 4. Renal Diseases Business: The Renal Diseases Business segment provides innovative solutions for patients with kidney diseases. This target group includes particularly patients suffering from life-threatening chronic kidney diseases and in need of a kidney transplant. In this context, the product "Nesp" (Darbepoetin alfa) was developed to stimulate erythropoietin production, which promotes the formation of red blood cells. Kyowa Kirin Co Ltd is committed to improving lives and developing life-saving treatments for patients. The company employs a highly diversified business strategy. The aim is to increase the profitability of each business segment by combining the company's strengths in areas such as drug development, analysis and synthesis technology, clinical trials, production, and distribution. As a leading pharmaceutical company, Kyowa Kirin Co Ltd strives to continuously provide high-quality services to patients. To achieve this, the company collaborates closely with partners from the scientific and industrial sectors, as well as patient organizations worldwide. Kyowa Kirin also aims to act responsibly and integrate sustainable practices into all aspects of its business.

Kyowa Kirin Co distribuie un dividend de 51,00 JPY în plăți anuale.

Dividenda nu poate fi calculată în prezent pentru Kyowa Kirin Co sau compania nu distribuie dividende.

Codul ISIN pentru Kyowa Kirin Co este JP3256000005.

Codul WKN al Kyowa Kirin Co este 858523.

Ticker-ul pentru Kyowa Kirin Co este 4151.T.

În ultimele 12 luni, Kyowa Kirin Co a plătit un dividend în valoare de 56,00 JPY . Aceasta corespunde unei randamente a dividendului de aproximativ 1,81 %. Pentru următoarele 12 luni, Kyowa Kirin Co va plăti probabil un dividend de 57,97 JPY.

Randamentul dividendelor pentru Kyowa Kirin Co este în prezent de 1,81 %.

Kyowa Kirin Co plătește un dividend trimestrial. Acesta este distribuit în lunile iulie, ianuarie, iulie, ianuarie.

Kyowa Kirin Co a plătit dividende în fiecare an, în ultimii 23 ani.

Pentru următoarele 12 luni se așteaptă dividende în valoare de 57,97 JPY. Acest lucru corespunde unei randamente a dividendelor de 1,87 %.

Kyowa Kirin Co este atribuit sectorului 'Sănătate'.

Pentru a primi ultimul dividend de Kyowa Kirin Co de la 01.03.2025 în valoare de 29 JPY, trebuia să deții acțiunea în portofoliu înainte de ziua Ex-Tag de pe 27.12.2024.

Ultima plată a dividendului a fost efectuată la 01.03.2025.

În anul 2023, Kyowa Kirin Co a distribuit 51 JPY sub formă de dividende.

Dividendele de la Kyowa Kirin Co sunt distribuite în JPY.